和邦生物
(603077)
| 流通市值：223.44亿 | | | 总市值：223.44亿 |
| 流通股本：88.32亿 | | | 总股本：88.32亿 |
| 利润表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 营业总收入 | 2,888,094,804.07 | 1,387,806,236.79 | 7,187,510,832.55 | 5,926,520,025.82 |
| 营业总成本 | 2,396,219,339.8 | 1,212,017,795.36 | 7,030,846,930.02 | 5,726,755,746.57 |
| 其他经营收益 | | | | |
| 营业利润 | 450,987,125.07 | 205,364,268.63 | -602,862,134.87 | 184,809,095.44 |
| 利润总额 | 450,569,752.05 | 205,064,249.94 | -630,842,405.14 | 170,421,441.55 |
| 净利润 | 374,581,964.58 | 172,284,616.8 | -712,664,631.51 | 76,442,914.44 |
| 每股收益 | | | | |
| 其他综合收益 | -35,768,548.06 | -20,318,866.56 | -28,120,800.15 | -18,262,832.26 |
| 综合收益总额 | 338,813,416.52 | 151,965,750.24 | -740,785,431.66 | 58,180,082.18 |
| 资产负债表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 流动资产: | | | | |
| 流动资产合计 | 13,144,256,104.89 | 12,469,906,514.03 | 12,024,378,519.31 | 13,074,335,916.87 |
| 非流动资产: | | | | |
| 非流动资产合计 | 16,496,413,988.13 | 16,249,413,053.17 | 16,185,065,118.18 | 16,219,656,664.39 |
| 资产总计 | 29,640,670,093.02 | 28,719,319,567.2 | 28,209,443,637.49 | 29,293,992,581.26 |
| 流动负债: | | | | |
| 流动负债合计 | 2,673,890,350.43 | 3,235,210,752.82 | 3,784,197,487.62 | 4,264,610,349.87 |
| 非流动负债: | | | | |
| 非流动负债合计 | 7,622,112,994.69 | 7,302,282,961.64 | 6,466,365,986.14 | 6,263,867,542.14 |
| 负债合计 | 10,296,003,345.12 | 10,537,493,714.46 | 10,250,563,473.76 | 10,528,477,892.01 |
| 所有者权益(或股东权益): | | | | |
| 归属于母公司股东权益合计 | 19,270,366,023.54 | 18,102,444,832.6 | 17,876,970,748.79 | 18,522,695,742.31 |
| 股东权益合计 | 19,344,666,747.9 | 18,181,825,852.74 | 17,958,880,163.73 | 18,765,514,689.25 |
| 负债和股东权益合计 | 29,640,670,093.02 | 28,719,319,567.2 | 28,209,443,637.49 | 29,293,992,581.26 |
| 现金流量表 |
| 报告期 | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
| 经营活动产生的现金流量: | | | | |
| 经营活动现金流入小计 | 2,380,677,867.08 | 1,147,456,205.7 | 6,656,590,933.72 | 4,794,461,851.95 |
| 经营活动现金流出小计 | 2,191,597,379.12 | 1,124,842,292.71 | 5,580,354,322.57 | 4,484,325,324.57 |
| 经营活动产生的现金流量净额 | 189,080,487.96 | 22,613,912.99 | 1,076,236,611.15 | 310,136,527.38 |
| 投资活动产生的现金流量: | | | | |
| 投资活动现金流入小计 | 29,516,363.23 | 11,292,473.28 | 195,363,461.91 | 131,673,249.59 |
| 投资活动现金流出小计 | 658,576,389.95 | 254,353,190.1 | 1,543,927,390.83 | 915,384,687.98 |
| 投资活动产生的现金流量净额 | -629,060,026.72 | -243,060,716.82 | -1,348,563,928.92 | -783,711,438.39 |
| 筹资活动产生的现金流量: | | | | |
| 筹资活动现金流入小计 | 3,073,802,317.83 | 1,574,485,716.12 | 3,974,928,220.33 | 3,517,758,172.21 |
| 筹资活动现金流出小计 | 2,032,796,709.84 | 1,205,223,740.69 | 3,831,504,911.89 | 3,069,863,950.87 |
| 筹资活动产生的现金流量净额 | 1,041,005,607.99 | 369,261,975.43 | 143,423,308.44 | 447,894,221.34 |
| 汇率变动对现金及现金等价物的影响 | -51,286,958.09 | -24,821,057.89 | -38,462,235.45 | -21,786,823.99 |
| 现金及现金等价物净增加额 | 549,739,111.14 | 123,994,113.71 | -167,366,244.78 | -47,467,513.66 |
| 期末现金及现金等价物余额 | 7,233,935,927.15 | 6,805,667,592.53 | 6,684,196,816.01 | 6,804,095,547.13 |
| 补充资料: | | | | |
| 现金及现金等价物的净增加额 | 549,739,111.14 | - | -167,366,244.78 | - |